Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Diabetologia

Volumn 59, Issue 9, 2016, Pages 2036-2039

  Fioretto, Paola ^a   Stefansson, Bergur V ^b   Johnsson, Eva ^b   Cain, Valerie A ^c   Sjöström, C David ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Albuminuria; Dapagliflozin; Renal impairment; SGLT2 inhibition; Type 2 diabetes

Indexed keywords

ALBUMIN; CREATININE; DAPAGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; URIC ACID; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; LETTER; MODERATE RENAL IMPAIRMENT; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; REDUCTION; RENAL PROTECTION; RENAL SYSTEM PARAMETERS; SYSTOLIC BLOOD PRESSURE; ULTRAFILTRATION; URINALYSIS; URINARY ALBUMIN CREATININE RATIO; URINARY EXCRETION; CHRONIC KIDNEY FAILURE; COMPLICATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; MALE; METABOLISM; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ALBUMINURIA; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; MALE; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84974816065     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4017-1     Document Type: Letter

References (6)

1. De Nicola L, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R (2014) Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis 64:16–24
2. Komala MG, Panchapakesan U, Pollock C, Mather A (2013) Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens 22:113–119
3. Schmieder RE, Schutte R, Schumacher H et al (2014) Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. Diabetologia 57:2019–2029
4. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjostrom CD (2016) Dapagliflozin reduces albuminuria in hypertensive diabetic patients using renin-angiotensin blockers. Diabetes Obes Metab 18:590–597
5. Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962–971
6. Wanner C, Lachin JM, Fitchett DH et al (2015) Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease. J Am Soc Nephrol 26: 1133, # HI-OR01 (Abstract)